within Pharmacolibrary.Drugs.ATC.L;

model L01ED04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.92,
    Cl             = 0.00021166666666666667,
    adminDuration  = 600,
    adminMass      = 180 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.153,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010333333333333333,
    Tlag           = 9.66,            
    Vdp             = 0.0979,
    k12             = 25,
    k21             = 25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01ED04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Brigatinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It is approved for use in patients whose disease has progressed on or who are intolerant to crizotinib.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in adult patients with advanced malignancies including ALK-positive NSCLC, mostly aged 18-84 years, under steady-state following repeated dosing.</p><h4>References</h4><ol><li><p>Tugnait, M, et al., &amp; Narasimhan, N (2019). The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 8(6) 734–741. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.641&quot;>10.1002/cpdd.641</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30570839/&quot;>https://pubmed.ncbi.nlm.nih.gov/30570839</a></p></li><li><p>Hanley, MJ, et al., &amp; Gupta, N (2023). Brigatinib pharmacokinetics in patients with chronic hepatic impairment. <i>Investigational new drugs</i> 41(3) 402–410. DOI:<a href=&quot;https://doi.org/10.1007/s10637-023-01339-6&quot;>10.1007/s10637-023-01339-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37052729/&quot;>https://pubmed.ncbi.nlm.nih.gov/37052729</a></p></li><li><p>Tugnait, M, et al., &amp; Narasimhan, N (2020). Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 9(2) 214–223. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.723&quot;>10.1002/cpdd.723</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31287236/&quot;>https://pubmed.ncbi.nlm.nih.gov/31287236</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01ED04;
